WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 15-July-2016 (15-July-2016)
Next overall update Fall 2016
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 7'9201 Infant (under 12 months) mortality rate: 112
GDP / capita (US$): 15'6051 Child (under 5 years) mortality rate: 132

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 6'278  6'259  6'266  6'283  6'289  5'337  4'398  3'191 
Births 129  132  135  137  139  117  126  129 
Surviving infants 126  129  132  134  135  114  121  122 
Pop. less than 5 years 649  658  671  682  683  555  638  589 
Pop. less than 15 years 1'873  1'857  1'849  1'843  1'831  1'759  1'835  1'527 
Female 15-49 years 1'735  1'744  1'757  1'771  1'781  1'408  967  619 

Number of reported cases

(Click for retrospective incidence data for Libya)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  372  320  931  1'547 
Mumps
ChartChart
  111 
Pertussis
ChartChart
  197  43  25 
Polio*
ChartChart
  30 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  30 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Libya)
Vaccine year result method % card seen                                                
BCG 2006  100  FHS   81  99*  99*  90  88 
DTP1 2006  100  FHS   81  98  99 
DTP3 2006  98  FHS   81  97  98  84  60 
DTP4          96 
IPV1          98 
HepB_BD          99*  99* 
HepB3          97  98 
Hib3          97  98 
JapEnc         
MCV1          98  98  89  61 
MCV2          97  97 
PCV1          98 
PCV3          97 
Pol3 2006  98  FHS   81  97  98  84  60 
Rota1          98 
RotaC          97 
Rubella1          98  98 
TT2plus          18 
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Libya)
BCG
ChartChart
  99  99  99  99  99  98  90  88 
DTP1
ChartChart
  96  96  98  99  99  97  94  82 
DTP3
ChartChart
  94  94  96  98  98  94  84  60 
HepB3
ChartChart
  94  94  96  98  98  92 
HepB_BD
ChartChart
  99  99  99  99  99 
Hib3
ChartChart
  94  94  96  98  98 
MCV1
ChartChart
  93  93  96  98  98  93  89  61 
MCV2
ChartChart
  92  92  95  97  97 
PCV3
ChartChart
  39  39 
Pol3
ChartChart
  94  94  96  98  98  94  84  60 
RCV1
ChartChart
  93  93  96  98  98  93 
RotaC
ChartChart
  86  86 

Number of districts in the country 32  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 84
From 80 to 89% 16
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTaPHibHepIPV 2, 4, 6 months;
DTwP 18 months; Yes
HPV 15 years (3 doses); Yes
HepB birth; Yes and not vaccinated adults
IPV 14 weeks; Yes
Influenza >60 years Yes Elderly with chronic illness, pregnant women, health care workers, Hajj and other travellers
MMR 12, 18 months; Yes
MenACWY 9,12 months; 6 years; Yes
OPV birth; 2, 4, 6, 18 months; 6,15 years; Yes
Pneumo_conj 2, 4, 12 months; Yes
Pneumo_ps Yes adults - risk groups
Rotavirus 2, 4, 6 months; Yes
Td 6, 15 years; Yes
YF Yes travelers

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR   No    Yes      Yes 
What years does the MYP cover? number       2008-2012      2008-2012 
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number   32    30      23 
Nº districts with DTP3 coverage >=80% number   32    30      23 
% of districts with DTP3 coverage >=80% From 0 to 100%   100    100      100 
Nº districts with measles (MCV1) coverage >=95% number     17      16 
% of districts with MCV1 coverage >=95% From 0 to 100%   19    57      70 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND   Yes    Yes       
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR   No    No      No 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%             100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR   Yes    Yes       

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.